Cephalon Inc. said Wednesday that when Myotrophin, thecompany's lead compound for amyotrophic lateral sclerosis andperipheral neuropathy, was administered daily by subcutaneousinjection, it produced no significant side effects and waswell-tolerated in healthy volunteers.

In a Phase I safety trial, conducted in the United Kingdom with48 healthy volunteers, Myotrophin was administered in fourescalating doses with each dose given for seven consecutivedays.

(c) 1997 American Health Consultants. All rights reserved.